S-adenosylmethionine (SAMe)
S-Adenosyl-L-Methionine (SAMe) · also known as SAMe, Ademetionine, Ademetionine
SAMe is an important methyl donor for many methyltransferases. Oral doses can raise SAM levels in the blood, but the effect on methylation in tissues varies between people. Evidence that it raises liver glutathione is also inconsistent.
Clinical uses and human evidence
Low mood
Studies (3)
- Limveeraprajak 2024 · Prog Neuropsychopharmacol Biol Psychiatry · Meta-analysis · n=2183 — Efficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta- analysis
- Sarris 2020 · Psychopharmacology (Berl) · RCT · n=49 — S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial
- Mischoulon 2014 · J Clin Psychiatry · RCT · n=189 — A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder
Osteoarthritis pain
Fatty liver and liver enzymes
All-cause mortality risk
Mechanisms of action
One-carbon cycle methyl donor (SAMe) regeneration and Hcy clearance
SAMe is an important donor for many methyltransferases. Studies in people with liver disease and in healthy people both show that oral SAMe raises serum or plasma SAM. That does not mean methylation flux rises markedly in every tissue, or that SAMe directly promotes homocysteine remethylation.
References (2)
- Medici et al. 2011 · RCT in 37 patients with liver disease: with 1.2 g/day orally, serum SAM was higher than in the placebo group during follow-up
- Cameron et al. 2020 · Pharmacokinetic study in healthy people: 400–800 mg taken orally can increase plasma SAM exposure, and exposure differs between formulations
Substrate and cofactor supply for glutathione (GSH) synthesis
After donating its methyl group, SAMe becomes homocysteine, which the transsulfuration pathway converts to cysteine, indirectly supplying raw material for glutathione synthesis. One small controlled study found higher glutathione in liver biopsies, but another randomized trial found no significant change in serum glutathione.
Safety and drug interactions
Serotonin excess risk
Involved in making monoamine neurotransmitters. Each of these raises serotonin levels in the brain. Taking two or more together carries a risk of serotonin syndrome, which causes agitation, sweating, a fast heartbeat, muscle twitching and fever. In severe cases it can be life-threatening.
With SSRIs, SNRIs and other serotonergic drugs High risk
May enhance the drug’s effects and trigger serotonin syndrome. Use only under a doctor’s supervision.
With MAO inhibitors High risk
May trigger serotonin syndrome.